| 发明名称 |
TREATMENT OF CYR61- AND VEGF-MEDIATED CONDITIONS |
| 摘要 |
The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual. |
| 申请公布号 |
US2016213696(A1) |
申请公布日期 |
2016.07.28 |
| 申请号 |
US201414917098 |
申请日期 |
2014.09.04 |
| 申请人 |
VANDA PHARMACEUTICALS INC. |
发明人 |
POLYMEROPOULOS Mihael H.;LICAMELE Louis William;LAVEDAN Christian |
| 分类号 |
A61K31/704;A61K9/00;A61K31/351 |
主分类号 |
A61K31/704 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising:
administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual. |
| 地址 |
Washington DC US |
